Hutchmed (HCM) said Monday that the China National Medical Products Administration accepted the new drug application for fanregratinib as a potential treatment for adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma and gave the application priority review status.

The company said the application is backed by data from a phase 2 study in China, which met its primary endpoint of objective response rate.